This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Mucuna Pruriens
Velvet bean (Mucuna pruriens) seed is a botanical L-DOPA bomb — 4-7% levodopa by weight, pharmacologically identical to the molecule in Sinemet.
Aliases (1)
Overview
What is Mucuna Pruriens?
Velvet bean (Mucuna pruriens) seed is a botanical L-DOPA bomb — 4-7% levodopa by weight, pharmacologically identical to the molecule in Sinemet. Real, measurable effects on dopamine, prolactin, and (per Shukla 2009) testosterone in fertility-impaired men. Real Parkinson efficacy non-inferior to carbidopa/levodopa in five small RCTs. But it's still L-DOPA — same dyskinesia, on-off phenomena, dopamine dysregulation syndrome, and pulsatile-receptor problems as the pharmaceutical. WATCH-LIST for a 20-year-old MMA athlete with normal cortisol, normal libido, and zero motivation deficit — there is no daily-use case here, only narrow tactical windows (4-week prolactin-suppression cycle if labs show high PRL, or a single-shot pre-event dopaminergic push). Sourcing is treacherous — commercial extracts run from 6% to 143% of label claim and 228%-2186% above the seed-equivalent L-DOPA quantity stated on the label. Skip if drug-tested (L-DOPA shows on broad metabolite panels), on any MAOI/SSRI/antipsychotic, or planning >4 continuous weeks of use.
Peptide Interactions
phenelzine, tranylcypromine — risk of hypertensive crisis (peripheral L-DOPA → NE accumulation). Same contraindication as pharmaceutical levodopa + MAOI. Sel…
haloperidol, risperidone, olanzapine, metoclopramide, prochlorperazine. Mucuna's effect is blocked; antipsychotic efficacy may also be compromised. Pharmacod…
bromocriptine, cabergoline, pramipexole, ropinirole, amphetamines, methylphenidate, modafinil chronic, bromantane — additive dopaminergic load, additive down…
Iron chelates L-DOPA, reduces absorption. Separate by 2+ hours.
LAT1 competition. Empty-stomach rule is real.
Theoretical serotonin syndrome risk via the trace serotonin/tryptamine content + L-DOPA → BH4 competition affecting 5-HT synthesis. Clinically rare but worth…
AADC substrate competition — both 5-HTP and L-DOPA use the same enzyme. Co-administration reduces conversion of both; chronic use can deplete the unaccompani…
What to Expect
- Week 1Tolerability and dose-response.
- Week 2-4Early effect window.
- Week 4-8Peak benefit assessment.
- Week 8+Cycle decision point.
Side Effects & Safety 12
Side Effects
- 1Nausea / GI upset — peripheral dopamine action on the chemoreceptor trigger zone. The single most common reason users quit. Mitigations: food (compromises efficacy), ginger, lower dose, B6 co-administration.
- 2Tolerance within 2-3 weeks — community aggregate flags this consistently. The motivation/mood effect dulls; the side-effect profile does not.
- 3Sleep disruption — even AM dosing can shorten REM and increase nocturnal awakenings.
- 4Orthostatic hypotension and dizziness
- 5Mild palpitations / HR elevation
- 6Headache (~10%)
- 7Anxiety / agitation (especially in anxious-baseline users)
- 8Loose stool / diarrhea
- 9Vivid or unsettling dreams
- 10Mild dyskinesia-like sensations (involuntary jaw/tongue movement) at high doses
- 11Transient mood crash 4-8 hours post-dose ("off-state")
- 12Reduced libido on chronic daily use (paradoxical to acute effect — receptor downregulation)
When to Stop
- Dopamine dysregulation syndrome (DDS) — compulsive overuse, escalation, impulse-control disorder. Sohutskay 2024 case (PMC11300383) established this can occur from herbal L-DOPA, not just pharmaceutical.
- Drug-induced psychosis — hallucinations, paranoia, Othello syndrome (case-documented at very high chronic doses).
- Dyskinesias — involuntary motor movements, predominantly orofacial. Risk rises with chronic exposure and pulsatile dosing (i.e., no DDC inhibitor + on-off kinetics).
- Hypertensive crisis — when combined with MAOIs (non-selective). Pharmacologically the same as the L-DOPA + MAOI contraindication in PD.
- Serotonin depletion — chronic L-DOPA can deplete CNS serotonin via BH4 competition; clinical relevance in healthy short-term users unclear.
- Cowhage itch (cutaneous) — *the unprocessed seed hairs* contain mucunain (a histamine-releasing protease) that causes severe contact urticaria. Properly prepared seed powder and extracts are itch-free; but handling raw, unroasted seed pods is dermatologically hazardous. Relevant only for users sourcing wild/raw material.
- Days 1-7: Acute tolerability — nausea, orthostasis, sleep. Many users quit here.
- Weeks 2-4: Tolerance onset — subjective benefit fades while side-effect risk persists.
- Weeks 4-8 (if continued): Receptor downregulation territory. This is where you stop. Beyond this, on/off phenomena, mood crashes between doses, and DDS escalation risk become non-trivial.
- First 2 weeks of cessation: Watch for rebound prolactin elevation, transient low mood, and (rare) PAWS-like dopaminergic dysregulation.
References
Cilia et al. 2017 — Mucuna pruriens in PD double-blind RCT crossover (PMID 28679598)
strongest single trial; high-dose MP outperformed standard levodopa on motor outcomes
View StudyKatzenschlager et al. 2004 — Mucuna pruriens in PD double-blind crossover (PMID 15548480)
established faster onset, larger AUC, longer ON duration vs levodopa/carbidopa
View StudyHammoud et al. 2025 — Mucuna pruriens in PD systematic review (PMID 40860042)
5-RCT pooled analysis; consistent benefit + no dyskinesia in trial populations
View StudyCilia et al. 2026 — 12-month Mucuna RCT in sub-Saharan Africa (PMID 41269916)
longest prospective MP monotherapy data
View StudyHP-200 in Parkinson's Disease Study Group 1995 multicenter trial (PMID 9395621)
n=60 open trial, significant H-Y and UPDRS reductions
View StudyShukla et al. 2009 — Mucuna pruriens improves male fertility via HPG axis (PMID 18973898)
core fertility/T paper
View StudyShukla et al. 2010 — Mucuna pruriens reduces stress + improves semen (PMID 18955292)
companion paper on oxidative-stress + seminal antioxidant status
View StudySohutskay et al. 2024 — Dopamine dysregulation syndrome from MP (PMC11300383)
first published herbal-L-DOPA DDS case
View StudyManyam et al. 2004 — HP-200 central monoamine effects in rats (PMID 15022157)
suggests non-L-DOPA contribution to antiparkinson effect
View StudyLevodopa in Mucuna pruriens and its degradation — Scientific Reports 2015
analytical chemistry of L-DOPA stability in mucuna preparations
View StudyLevodopa Content of Mucuna pruriens Supplements — NIH DSLD analysis (PMC9361182)
228%-2186% deviation from label-claim quantities
View StudyAnalysis of Levodopa Content in Commercial Mucuna Formulations (PMC5808387)
quantitative analysis of commercial extracts
View StudyLampariello / Frontiers Chemistry 2025 — quality assessment of high-percentage L-DOPA supplements
supplement label vs analytical reality
View StudyAntiparkinsonian + antidyskinetic mechanisms of MP in MPTP-treated nonhuman primate (PMC3445014)
proposed serotonin-mediated antidyskinetic mechanism
View StudyExamine.com — Mucuna pruriens monograph
concise commercial-grade review of evidence
View StudyNutraIngredients 2022 — wide L-DOPA variation in commercial MP supplements
popular-press coverage of the 6-brand 6%-143% label-claim analysis
View StudyLONGECITY forum thread — dopamine receptor downregulation and tolerance with MP
community-level discussion of tolerance trajectory
View Studydopamine.club Mucuna pruriens community aggregate
source of the embedded community-data block above (341 community reports, 140 referenced studies)
View StudyLatest research
- rctMucuna pruriens in untreated PD in sub-Saharan Africa — 12-month multicenter RCTCilia et al., J Parkinsons Dis 2026. n=32 untreated PD. Roasted MP seed powder monotherapy vs standard levodopa/DDC inhibitor for 12 months. Demonstrated feasibility, real-world efficacy, and tolerability of unrefined MP as a monotherapy levodopa source in resource-limited settings.
- systematic-reviewMucuna pruriens Treatment for Parkinson Disease — Systematic Review of Clinical TrialsFive RCTs / 108 patients pooled. M. pruriens shortened time-to-ON, prolonged ON duration, and produced fewer adverse events than standard carbidopa/levodopa, with no dyskinesia reported in any included trial. Evidence base remains small (1 high-quality, 1 some-concerns, 3 low-quality).
- case-reportDopamine Dysregulation Syndrome Presenting as Overuse of Mucuna pruriensSohutskay et al., J Mov Disord 2024. 59F with PD escalated to ~100 capsules/2 days over 5 years of MP self-supplementation; developed dyskinesias, hallucinations, Othello syndrome, and compulsive medication-seeking behavior. First published dopamine dysregulation syndrome attributed to an herbal L-DOPA source.
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.